SLC5A2 and Stroke: Notably, clinical evidence suggests that GLP-1 receptor agonists exhibit stronger efficacy than SGLT2 inhibitors in reducing atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke [157].